In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Actinium Pharmaceuticals (ATNM). The company’s shares closed yesterday at $0.55.
According to TipRanks.com, Singh is a 3-star analyst with an average return of 3.2% and a 46.8% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actinium Pharmaceuticals with a $4 average price target, representing a 627.3% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.33. Currently, Actinium Pharmaceuticals has an average volume of 770.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
